At Fosun Health, lymphoma diagnosis is not just about "finding a lump" —it is about determining the exact subtype (Hodgkin vs. non Hodgkin, B cell vs. T cell, indolent vs. aggressive), mapping genetic drivers, and stratifying risk to design a personalized plan that maximizes cure while minimizing long term side effects. Our streamlined pathway delivers answers within days:
The gold standard. We remove an entire lymph node (excisional biopsy) or take a large core of tissue (core needle biopsy) under ultrasound/CT guidance. Fine needle aspiration is insufficient for initial diagnosis. The sample is examined for architecture (effacement of normal nodes), cell size, and mitotic rate.
Uses antibodies to detect surface markers (CD20, CD3, CD30, CD15, MUM1, BCL2, BCL6, MYC, Ki-67, etc.) to determine cell lineage (B vs. T), differentiation stage, and proliferation index. This distinguishes diffuse large B-cell lymphoma (DLBCL) from follicular lymphoma, Burkitt, mantle cell, Hodgkin, etc.
For blood, bone marrow, or fresh lymph node tissue. Rapidly identifies clonal B-cells or aberrant T-cell populations, and measures markers for minimal residual disease (MRD) monitoring.
The most important staging tool. Detects all involved lymph node regions (neck, chest, abdomen, pelvis) and extranodal sites (spleen, liver, bone, lung). PET-CT determines Ann Arbor stage (I-IV) and provides baseline for response assessment (Deauville score) after treatment.
Using tumor tissue, we analyze MYC, BCL2, BCL6 rearrangements (FISH) for double-hit/triple-hit lymphoma ; TP53, EZH2, CREBBP, NOTCH1, BRAF mutations; and over 300 lymphoma-related genes. This determines whether your lymphoma will respond to BTK inhibitors (ibrutinib, zanubrutinib, orelabrutinib) for mantle cell or CLL, BCL2 inhibitor (venetoclax) for t(14;18) positive follicular or CLL, EZH2 inhibitors (tazemetostat) for EZH2 mutant follicular lymphoma, ALK inhibitors (crizotinib, alectinib) for ALK positive anaplastic large cell lymphoma, PD-1 inhibitors (nivolumab, pembrolizumab, sintilimab, camrelizumab) for Hodgkin lymphoma and certain T-cell lymphomas, or bispecific antibodies (CD20×CD3, CD19×CD3) and CAR-T therapy for relapsed/refractory B-cell lymphomas.
